Literature DB >> 12854091

Novel designs for multi-arm clinical trials with survival outcomes with an application in ovarian cancer.

Patrick Royston1, Mahesh K B Parmar, Wendi Qian.   

Abstract

With the increasing pace of drug development, it is not unusual for several promising treatment regimens to be ready simultaneously for testing in a randomized phase III setting. Various limiting factors, including the time needed to transfer research results to clinical practice and a narrow 'window of opportunity', may make it unfeasible to perform trials to test such regimens sequentially against a control treatment in a traditional two-arm parallel group design. We present an approach to trial design based on eliminating inferior contenders at an early stage, allowing through to a second stage only treatments that show a predefined degree of advantage against a control treatment. The first stage of testing utilizes a marker known to be a valid intermediate outcome measure or surrogate for the definitive outcome. The experimental arms are compared pairwise with control according to this intermediate outcome measure. Arms that survive the comparison enter a second stage of patient accrual culminating in comparisons against control on the outcome measure of primary interest. We show how the design may be realized in practice by considering hypothetically distinct trials at stages 1 and 2, each with their own operating characteristics. The overall operating characteristics are computed from the stage 1 and 2 size and power and the correlation between the treatment effects on the intermediate and primary outcome measures according to a bivariate Normal approximation. The correlation is estimated by bootstrapping individual patient data from previous trials. We illustrate the general approach in a design of a real trial of four new chemotherapy regimens for advanced ovarian cancer. The intermediate outcome measure is progression-free survival. An international randomized controlled trial using the new design is already under way. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2003        PMID: 12854091     DOI: 10.1002/sim.1430

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  44 in total

1.  A modest proposal for dropping poor arms in clinical trials.

Authors:  Michael A Proschan; Lori E Dodd
Journal:  Stat Med       Date:  2014-04-22       Impact factor: 2.373

2.  Design of a Randomized Controlled Trial for Ebola Virus Disease Medical Countermeasures: PREVAIL II, the Ebola MCM Study.

Authors:  Lori E Dodd; Michael A Proschan; Jacqueline Neuhaus; Joseph S Koopmeiners; James Neaton; John D Beigel; Kevin Barrett; Henry Clifford Lane; Richard T Davey
Journal:  J Infect Dis       Date:  2016-02-11       Impact factor: 5.226

3.  Randomized phase II/III confirmatory treatment selection design with a change of survival end points: Statistical design of Radiation Therapy Oncology Group 1216.

Authors:  Qiang Ed Zhang; Qian Wu; Paul M Harari; David I Rosenthal
Journal:  Head Neck       Date:  2018-12-14       Impact factor: 3.147

4.  Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.

Authors:  Michael A Bookman; Mark F Brady; William P McGuire; Peter G Harper; David S Alberts; Michael Friedlander; Nicoletta Colombo; Jeffrey M Fowler; Peter A Argenta; Koen De Geest; David G Mutch; Robert A Burger; Ann Marie Swart; Edward L Trimble; Chrisann Accario-Winslow; Lawrence M Roth
Journal:  J Clin Oncol       Date:  2009-02-17       Impact factor: 44.544

5.  Methods of designing two-stage winner trials with survival outcomes.

Authors:  Fang Fang; Yong Lin; Weichung J Shih; Yulin Li; Jay Yang; Xiaosha Zhang
Journal:  Stat Med       Date:  2013-12-18       Impact factor: 2.373

Review 6.  Integrated phase II/III clinical trials in oncology: a case study.

Authors:  Meihua Wang; James J Dignam; Qiang E Zhang; John F DeGroot; Minesh P Mehta; Sally Hunsberger
Journal:  Clin Trials       Date:  2012-11-22       Impact factor: 2.486

Review 7.  The future of clinical trials in urological oncology.

Authors:  Vikram M Narayan; Philipp Dahm
Journal:  Nat Rev Urol       Date:  2019-10-11       Impact factor: 14.432

8.  Stopping clinical trials early for futility: retrospective analysis of several randomised clinical studies.

Authors:  M Jitlal; I Khan; S M Lee; A Hackshaw
Journal:  Br J Cancer       Date:  2012-08-09       Impact factor: 7.640

9.  Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial.

Authors:  Matthew R Sydes; Mahesh K B Parmar; Nicholas D James; Noel W Clarke; David P Dearnaley; Malcolm D Mason; Rachel C Morgan; Karen Sanders; Patrick Royston
Journal:  Trials       Date:  2009-06-11       Impact factor: 2.279

10.  Evaluating many treatments and biomarkers in oncology: a new design.

Authors:  Richard Kaplan; Timothy Maughan; Angela Crook; David Fisher; Richard Wilson; Louise Brown; Mahesh Parmar
Journal:  J Clin Oncol       Date:  2013-11-18       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.